Ultragenyx Pharmaceutical Inc.
For the period ended Jun 30, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share amounts)
| June 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents(1) | $176,306 | $173,729 |
| Marketable debt securities | 311,279 | 436,296 |
| Accounts receivable, net | 124,464 | 121,801 |
| Inventory | 46,498 | 45,007 |
| Prepaid expenses and other assets | 61,241 | 40,290 |
| Total current assets | 719,788 | 817,123 |
| Property, plant, and equipment, net | 255,763 | 265,929 |
| Marketable debt securities | 51,454 | 135,004 |
| Intangible assets, net | 174,733 | 178,314 |
| Goodwill | 44,406 | 44,406 |
| Other assets | 60,121 | 62,680 |
| Total assets | $1,306,265 | $1,503,456 |
| LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $34,242 | $38,756 |
| Accrued liabilities | 180,792 | 240,973 |
| Lease liabilities | 11,766 | 10,297 |
| Liabilities for sales of future royalties | 63,863 | 49,847 |
| Other liabilities | 2,581 | 4,280 |
| Total current liabilities | 293,244 | 344,153 |
| Lease liabilities | 24,531 | 30,042 |
| Deferred tax liabilities | 30,058 | 30,058 |
| Liabilities for sales of future royalties | 782,748 | 819,824 |
| Other liabilities | 17,398 | 17,082 |
| Total liabilities | 1,147,979 | 1,241,159 |
| Noncontrolling interest | 7,000 | 7,000 |
| Stockholders’ equity: | ||
| Preferred stock, par value of $0.001 per share—25,000,000 shares authorized; nil outstanding in 2025 and in 2024 | — | — |
| Common stock, par value of $0.001 per share—250,000,000 shares authorized; outstanding—96,353,634 in 2025 and 92,484,330 in 2024 | 96 | 92 |
| Treasury stock, at cost, 173,034 in 2025 and 69,757 in 2024 | (7,991) | (3,593) |
| Deferred compensation obligation | 7,991 | 3,593 |
| Additional paid-in capital | 4,374,333 | 4,212,692 |
| Accumulated other comprehensive loss | (268) | (643) |
| Accumulated deficit | (4,222,875) | (3,956,844) |
| Total stockholders’ equity | 151,286 | 255,297 |
| Total liabilities, noncontrolling interest and stockholders’ equity | $1,306,265 | $1,503,456 |
(1)
The Company's Condensed Consolidated Balance Sheet as of June 30, 2025 and December 31, 2024, includes $10.2 million and $13.5 million, respectively, in cash and cash equivalents that can be used only to settle obligations of the consolidated variable interest entity. See Note 6.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.